National Bank of Denmark Governor Christian Kettel Thomsen announced plans to substantially reduce the country’s economic growth forecast, attributing the revision to slowing sales growth at Novo Nordisk. The pharmaceutical company, known for its blockbuster drugs Wegovy and Ozempic, has become Denmark’s most critical firm, driving exports, tax revenue, and employment in recent years. This development underscores the economy’s heavy reliance on a single corporate performer and highlights vulnerabilities to sector-specific slowdowns. The central bank’s adjustment signals broader caution about near-term economic resilience amid global market pressures.
about Denmark Cuts Growth Forecast as Novo Nordisk Slows